Rapid detection of Golgi protein 73 by MAGLUMI chemiluminescent immunoassay and the clinical value to liver fibrosis/cirrhosis patients with chronic liver disease
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1576045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Lu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Liver Diseases, Membrane Proteins, Liver Cirrhosis, Immunoassay. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate the diagnostic value of MAGLUMI chemiluminescent immunoassay (CLIA) for detecting Golgi protein 73 (GP73) in patients with chronic liver disease.
Methods
A total of 212 patients with chronic liver disease were selected as the research subjects. METAVIR pathological staging was performed according to LSM values, and GP73 levels were detected by CLIA. Spearman analysis was used to analyze the correlation between GP73, LSM and METAVIR staging. The diagnostic efficacy of GP73 was analyzed using the ROC curve based on METAVIR staging.
Results
The enrolled patients included 37 patients in F0/F1, 80 patients in F2, 61 patients in F3, and 34 patients in F4. There were significant differences in GP73 levels in each stage ( p <0.001 for all stages). Spearman correlation analysis showed that GP73 levels were positively correlated with LSM and METAVIR stages. The AUC of GP73 in diagnosing significant liver fibrosis (F≥2), advanced liver fibrosis (F≥3), and cirrhosis (F=4) were 0.78 (95% CI: 0.72~0.84, p <0.0001), 0.83 (95% CI: 0.75~0.89, p <0.0001), 0.90 (95% CI: 0.80~0.96, p <0.0001), respectively.
Conclusion
GP73 detected by CLIA was positively correlated with liver fibrosis stage and LSM, and had important clinical value in diagnosis of liver fibrosis and cirrhosis in patients with chronic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, China.
- Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
- Research & Development Department, Shenzhen New Industries Biomedical Engineering, Shenzhen, Guangdong, China.
Zitieren
APA
Wang, L., Dai, W., Rao, J., Wang, Y., Liu, K., Li, X., Wang, H., Ye, J., Fang, Z., & Zheng, X. (2025). Rapid detection of Golgi protein 73 by MAGLUMI chemiluminescent immunoassay and the clinical value to liver fibrosis/cirrhosis patients with chronic liver disease. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1576045
Vancouver
Wang L, Dai W, Rao J, Wang Y, Liu K, Li X, et al. Rapid detection of Golgi protein 73 by MAGLUMI chemiluminescent immunoassay and the clinical value to liver fibrosis/cirrhosis patients with chronic liver disease. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1576045
BibTeX
@article{Wang2025,
author = {Wang, Lu and Dai, Wen and Rao, Jie and Wang, Yichen and Liu, Kun and Li, Xing and Wang, Hua and Ye, Jiahuan and Fang, Zhonggang and Zheng, Xin},
title = {Rapid detection of Golgi protein 73 by MAGLUMI chemiluminescent immunoassay and the clinical value to liver fibrosis/cirrhosis patients with chronic liver disease},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1576045}
}
EUVIMED